The Observation of Clinical Efficacy of Different Doses of Rituximab in Treatment of Chronic ITP

Abstract：Objective:To observe the clinical efficacy and safety of different doses of Rituximab in treatment of chronic ITP. Method:The clinical data of 44 patients with chronic ITP from July 2011 to July 2013 were analyzed. In those cases,22 patients of standard dose were treated with Rituximab(375 mg/m2 per week for four weeks),22 patients of lower dose group were treated with Rituximab(100 mg/m2 per week for four weeks),platele count were detected before and after Rituximab therapy,the clinical efficacy and side effect were compared. Result:The two groups of patients with platelet count were significantly increased after treatment compared with before treatment,and the differences were statistically significant(P<0.05). The difference of the platelet counts on average between the two groups after 1 months and 3 months treatment were no statistically significant(P>0.05). The difference of the complete remission rate and effective rate between the two groups after 3 months treatment were no statistically significant(P>0.05). And there were no severe adverse effects during Rituximab therapy in two groups. Conclusion:The two doses of Rituximab in the treatment of chronic ITP have good efficacy. The lower dose rituximab may be an effective and safe modality for patients with chronic ITP,is worthy of promotion.